Ikonisys SA Welcomes US Sales Director, Accelerating Its Growth and Expansion Plans in the USA
30 Septembre 2021 - 5:45PM
Business Wire
Regulatory News:
Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO)
(Paris:ALIKO), a company specializing in the early and accurate
detection of cancer with a unique fully-automated solution for
medical analysis laboratories, is very pleased to announce that
diagnostic industry veteran, Manny Iglesias, joins as Ikonisys’
Sales Director for the US market. Manny’s responsibilities will
encompass accelerating Ikoniscope20 sales by strengthening
Ikonisys’ presence and acquiring new customers, expanding in new
geographies, and contributing to the company’s marketing and
business strategies.
Manny brings over 30 years of sales and leadership experience to
Ikonisys, mostly spent in the diagnostics sector. Manny already
knows Ikonisys and the Ikoniscope well, having been the top-selling
representative during the launch of the first-generation
instrument. Manny gained expertise developing and leading
high-performance sales teams in North and Central America at Dako,
Leica Microsystems and CSI Laboratories. Additionally, he has a
proficiency in process improvement, change management, automation
and systems integration, developed during consulting experiences
with top firms including Accenture, Schneider Electric and Johnson
& Johnson. He is a graduate of the Georgia Institute of
Technology and holds an MBA from the Kelley School of Business,
Indiana University.
“Manny is an outstanding addition to our Ikonisys team, as he
brings a deep blend of both human skills and technical knowledge in
the diagnostics industry” said Jurgen Schipper, Chief Commercial
Officer of Ikonisys. “As Ikonisys continues its rapid growth
and focuses across the United States and Europe, Manny’s sales
leadership and extensive background in building strong customers
relationships will accelerate Ikonisys’ growth.” continued Jurgen
Schipper.”
“I am honored to be part of this new development phase for
Ikonisys and help to build on the solid foundation developed over
the last years. Ikonisys is perfectly positioned to help
laboratories transform their business with automation and
digitalization for higher diagnostic confidence and throughput, in
order to compete in the modern environment” stated Manny
Iglesias, Sales Director, US.
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare cells.
Ikonisys has received FDA clearance for several automated
diagnostic applications, which are also marketed in Europe under CE
certification. Through its breakthrough fluorescence microscopy
platform, the company continues to develop a stream of new tests,
including liquid biopsy tests based on Circulating Tumor Cells
(CTC).
For further information, please go to www.Ikonisys.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210930005672/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024